Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDK | P21741 | 4/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.46 |
| ▸ | FGF1 | P05230 | 1/20 | 0.44 |
| ▸ | FGF2 | P09038 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12767779 | 0.98 | MDK (0.50) | MDKFOLH1FGF1FGF2VEGFA | |
| SCHEMBL8120683 | 0.95 | MDK (0.53) | MDKFOLH1FGF1FGF2VEGFA | |
| SCHEMBL14500481 | 0.95 | MDK (0.52) | MDKFOLH1FGF1FGF2VEGFA | |
| SCHEMBL12147669 | 0.90 | MDK (0.50) | MDKFOLH1FGF1FGF2VEGFA | |
| SCHEMBL13475036 | 0.86 | FOLH1 (0.54) | FOLH1CAPN1PRSS1PRSS2PRSS3 | |
| SCHEMBL26081709 | 0.85 | MDK (0.54) | MDKFOLH1FGF1FGF2VEGFA | |
| SCHEMBL12147642 | 0.84 | FOLH1 (0.61) | FOLH1CAPN1PRSS1PRSS2PRSS3 | |
| SCHEMBL12767763 | 0.84 | FOLH1 (0.61) | FOLH1CAPN1PRSS1PRSS2PRSS3 | |
| SCHEMBL12743524 | 0.83 | FOLH1 (0.59) | FOLH1CAPN1PRSS1PRSS2PRSS3 | |
| SCHEMBL12972428 | 0.83 | FOLH1 (0.59) | FOLH1CAPN1PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910088-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7854919-B2 | Multivalent constructs for therapeutic and diagnostic applications | Bracco, Suisse SA (CH) | 2010-12-21 | — | — | US | disclosed |
| US-7666979-B2 | polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor | BRACCO INTERNATIONAL B.V. (NL) | 2010-02-23 | — | — | US | disclosed |
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-10-18 | — | — | US | disclosed |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | MDK 1723/4885FOLH1 84/4885FGF1 4306/4885 |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | MDK 1723/4885FOLH1 84/4885FGF1 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.